Tricuspid atresia primary prevention: Difference between revisions
No edit summary |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
Effective measures for the [[primary prevention ]] of [[tricuspid atresia]] as [[prenatal screening]] include [[fetal sonography]] between 10-14 weeks of [[pregnancy]] for measurement of nuchal translucency thickness, fetal [[echocardiography]] between 18-22 weeks of [[pregnancy]] | |||
== | ==Primary prevention == | ||
* Effective measures for the [[primary prevention ]] of [[tricuspid atresia]] as [[prenatal screening]] include:<ref name="GalindoComas2009">{{cite journal|last1=Galindo|first1=A.|last2=Comas|first2=C.|last3=Martínez|first3=J. M.|last4=Gutiérrez-Larraya|first4=F.|last5=Carrera|first5=J. M.|last6=Puerto|first6=B.|last7=Borrell|first7=A.|last8=Mortera|first8=C.|last9=de la Fuente|first9=P.|title=Cardiac defects in chromosomally normal fetuses with increased nuchal translucency at 10–14 weeks of gestation|journal=The Journal of Maternal-Fetal & Neonatal Medicine|volume=13|issue=3|year=2009|pages=163–170|issn=1476-7058|doi=10.1080/jmf.13.3.163.170}}</ref> | * Effective measures for the [[primary prevention ]] of [[tricuspid atresia]] as [[prenatal screening]] include:<ref name="GalindoComas2009">{{cite journal|last1=Galindo|first1=A.|last2=Comas|first2=C.|last3=Martínez|first3=J. M.|last4=Gutiérrez-Larraya|first4=F.|last5=Carrera|first5=J. M.|last6=Puerto|first6=B.|last7=Borrell|first7=A.|last8=Mortera|first8=C.|last9=de la Fuente|first9=P.|title=Cardiac defects in chromosomally normal fetuses with increased nuchal translucency at 10–14 weeks of gestation|journal=The Journal of Maternal-Fetal & Neonatal Medicine|volume=13|issue=3|year=2009|pages=163–170|issn=1476-7058|doi=10.1080/jmf.13.3.163.170}}</ref> | ||
Latest revision as of 19:50, 8 November 2020
|
Tricuspid atresia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Special Scenarios |
|
Case Studies |
|
Tricuspid atresia primary prevention On the Web |
|
American Roentgen Ray Society Images of Tricuspid atresia primary prevention |
|
Risk calculators and risk factors for Tricuspid atresia primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor-In-Chief:; Sara Zand, M.D.[2] Keri Shafer, M.D. [3] Priyamvada Singh, MBBS [4]; Assistant Editor-In-Chief: Kristin Feeney, B.S. [5]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
Effective measures for the primary prevention of tricuspid atresia as prenatal screening include fetal sonography between 10-14 weeks of pregnancy for measurement of nuchal translucency thickness, fetal echocardiography between 18-22 weeks of pregnancy
Primary prevention
- Effective measures for the primary prevention of tricuspid atresia as prenatal screening include:[1]
- Fetal sonography between 10-14 weeks of pregnancy for measurement of nuchal translucency thickness.
- Fetal echocardiography between 18-22 weeks of pregnancy
References
- ↑ Galindo, A.; Comas, C.; Martínez, J. M.; Gutiérrez-Larraya, F.; Carrera, J. M.; Puerto, B.; Borrell, A.; Mortera, C.; de la Fuente, P. (2009). "Cardiac defects in chromosomally normal fetuses with increased nuchal translucency at 10–14 weeks of gestation". The Journal of Maternal-Fetal & Neonatal Medicine. 13 (3): 163–170. doi:10.1080/jmf.13.3.163.170. ISSN 1476-7058.